Biocept Receives South Korean Patent for Primer-Switch Platform Used to Identify Rare Genetic Mutations, Including Cancer Bio...
06 July 2021 - 10:27PM
Business Wire
Expands company’s patent portfolio in pursuit
of worldwide intellectual property protection for proprietary
technology that detects biomarkers in tissue, blood, and
cerebrospinal fluid
Biocept, Inc. (NASDAQ: BIOC), a leading provider of molecular
diagnostic assays and services, has been awarded a South Korean
Patent for its Primer-Switch technology, which detects rare
mutations in circulating tumor DNA (ctDNA) using real-time PCR and
associated analysis methods. The patent (No. 2252447) is titled
Methods for Detecting Nucleic Acid Sequence Variants.
This is the fourth issued patent for the technology, which
identifies rare cancer biomarkers found in tissue, blood, and
cerebrospinal fluid (CSF). Primer-Switch provides a unique method
for specifically enriching patient specimens for mutations of
interest. It can be used to enhance the performance and specificity
of the PCR method, the most widely used amplification approach for
research and clinical diagnostic applications. It also enables the
interrogation of fragmented DNA that is often found in biological
fluids.
“Primer-Switch methodology adds to the capabilities of our
Switch-Blocker technology used in our Target Selector™ assays,
providing key information about cancer biomarkers to aid physician
decision-making, with the goal of improving outcomes for patients
with cancer,” said Michael Nall, Biocept's President and CEO. “Our
strong and growing intellectual property portfolio enables Biocept
to develop and commercialize our highly differentiated technologies
and testing services.”
Biocept’s core technologies and products are protected by more
than 70 issued patents in the U.S., EU, Australia, China, Japan,
and South Korea, as well as other countries. This includes
worldwide patent protection on its highly sensitive methods for
detecting cancer biomarkers that are used by physicians for
treatment decisions.
About Biocept
Biocept, Inc., develops and commercializes molecular diagnostic
assays that provide physicians with clinically actionable
information to aid in the diagnosis, treatment and monitoring of
patients with cancer. In addition to its broad portfolio of
blood-based liquid biopsy tests, the company has developed the
CNSide™ cerebrospinal fluid assay, designed to diagnose cancer that
has metastasized to the central nervous system. Biocept also is
leveraging its molecular diagnostic capabilities to offer
nationwide RT-PCR-based COVID-19 testing and services to support
public health efforts during this unprecedented pandemic. For more
information, visit www.biocept.com. Follow Biocept on Facebook,
LinkedIn and Twitter.
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based
upon current expectations or beliefs, as well as a number of
assumptions about future events. Although we believe that the
expectations reflected in the forward-looking statements and the
assumptions upon which they are based are reasonable, we can give
no assurance that such expectations and assumptions will prove to
have been correct. To the extent that statements in this release
are not strictly historical, including without limitation
statements regarding the capabilities of our Primer-Switch
technology (including its ability to enhance the performance and
specificity of the PCR method, to enable the interrogation of
fragmented DNA, and to provide key information cancer biomarkers to
aid physician decision-making), the strength, growth and benefits
of our intellectual property portfolio, and our development and
commercialization of molecular diagnostic assays and the benefits
of such assays, such statements are forward-looking, and are made
pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. The reader is cautioned not to put
undue reliance on these forward-looking statements, as these
statements are subject to numerous risks and uncertainties,
including the risk that our products and services may not perform
as expected and the risk that we may be unable to maintain
effective proprietary rights for our products and services, which
may result in our inability to compete effectively in our markets.
These and other risks are described in greater detail under the
"Risk Factors" heading of our Quarterly Report on Form 10-Q for the
quarter ended March 31, 2021, as filed with the Securities and
Exchange Commission (SEC) on May 12, 2021. The effects of such
risks and uncertainties could cause actual results to differ
materially from the forward-looking statements contained in this
release. We do not plan to update any such forward-looking
statements and expressly disclaim any duty to update the
information contained in this press release except as required by
law. Readers are advised to review our filings with the SEC, which
can be accessed over the Internet at the SEC's website located at
http://www.sec.gov/.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210706005201/en/
Media Contact: Andrea Sampson, Sampson PR Group
asampson@sampsonprgroup.com, 562-304-0301
Investor Contact: Jody Cain, LHA Investor Relations
Jcain@lhai.com, 310-691-7100
Biocept (NASDAQ:BIOC)
Historical Stock Chart
From Apr 2024 to May 2024
Biocept (NASDAQ:BIOC)
Historical Stock Chart
From May 2023 to May 2024